GREY:DGCRF - Post by User
Post by
ready2go1on Sep 23, 2010 9:41am
396 Views
Post# 17482926
share price
share priceAt Last!, as NBF said . What does this mean going forward. First of all there have been a number of discussions and opinions on how long it will take for PCA3 to receive FDA approval. I had the opportunity to sit down several weeks ago with a couple of urologists and get their take. Again these are not investors, who know nothing of Diagnocure other than the stories I tell them.
6-10 months was the consensus; no one said 12 months and they had a number of reasons why. (I wanted to video the talk and post on you tube but it was a no go.)
The numbers on the revenue side have not changed because the feeling is that this will be universally adopted once they receive the FDA stamp. $75 to $100 million the first full year on the market.
My local hospital (in the Top 5 according to U.S. News and Report) is now using the test on a regular basis. It was a feature story months ago in the health care section of the paper.
My take; no reason we should be under $2 at this point. We will make consistent gains at some point getting ready for FDA approval. As mentioned in an earlier post; Those that follow Gen-Probe look at this approval for PCA3 as a turning point for their company. I am looking at the $3.00 range prior to approval.